EPISODE · Jan 22, 2024 · 23 MIN
Few IPOs but plenty of follow-on for biotech in 2023
After a year of stark contrasts in the public and private equity markets for healthcare, 2024 is shaping up to be another mixed outlook. While biotech continues to bolster the market, albeit more in follow-on offerings than IPOs, and HCIT and healthcare services have tailwinds, the medtech and value-based care subsectors have challenges as well as opportunities. Join our Co-Heads of Healthcare Equity Markets for their insights into the year ahead.
Embed this episode
NOW PLAYING
Few IPOs but plenty of follow-on for biotech in 2023
0:00
23:35
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Pathfinders in Biopharma?
This episode is 23 minutes long.
When was this Pathfinders in Biopharma episode published?
This episode was published on January 22, 2024.
Can I download this Pathfinders in Biopharma episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!